CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
San Francisco, California, United States and 84 other locations
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors....
Phase 1
Stanford, California, United States and 53 other locations
inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Ph...
Phase 1
San Francisco, California, United States and 63 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
San Francisco, California, United States and 957 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
San Francisco, California, United States and 33 other locations
known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-...
Phase 1, Phase 2
San Francisco, California, United States and 27 other locations
pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite ...
Phase 1
San Francisco, California, United States and 28 other locations
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorec...
Phase 1, Phase 2
Stanford, California, United States and 10 other locations
2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, gastric/gastroesophageal junction cancer, bl ...
Phase 1
San Francisco, California, United States and 11 other locations
evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors...
Phase 1, Phase 2
San Francisco, California, United States and 233 other locations
Clinical trials
Research sites
Resources
Legal